Signals, Powered By EquityPandit
The US health regulator has given its tentative approval to Glenmark Pharmaceuticals for its generic version of Vimpat Oral Solution that is used in treatment of epilepsy.
It said in a BSE filing that “Glenmark Pharmaceuticals Inc, USA has been granted tentative approval by the US Food and Drug Administration (USFDA) for its Lacosamide Oral solution, 10 Mg/mL, the generic version of Vimpat Oral Solution, 10 Mg/mL of UCB, Inc.”
This product will be marketed by the company upon receiving final approval of Lacosamide Oral solution, 10 Mg/mL.
It further said that “The patent listed in the Orange Book for Vimpat Oral Solution, 10 Mg/mL is scheduled to expire on March 17, 2022.”
